Is Neuralink Developing Vision Devices? Eye Prosthetics Update
- Neuralink is developing Blindsight, a brain implant meant to restore a basic form of vision by sending electrical signals directly to the visual cortex, bypassing the eyes.
- Unlike eye prosthetics, which work through the retina or optic nerve, Blindsight could help people whose eyes or optic nerves no longer work, and it received an FDA Breakthrough Device Designation in September 2024.
- Elon Musk has said Neuralink aims to restore limited sight to completely blind people, but no human Blindsight trial had launched as of October 2026.
What Blindsight is
Blindsight is Neuralink's planned vision product, following Telepathy, the motor-control implant now used by participants in its trials. The implant would target the visual cortex, so it could work even when the eyes or optic nerves do not, as long as the visual cortex is intact. Elon Musk first described Blindsight in detail in 2024.
People can join a registry on Neuralink's visual prosthesis page to be told when US trials launch. Musk has said early vision will look like low-resolution graphics, similar to early video games, and that later versions could exceed natural sight, including infrared detection. The World Health Organization estimates that 2.2 billion people live with some form of vision impairment.
Neuralink raised $650 million in a Series E in June 2025, which funds its trials and manufacturing.
How Blindsight would work
A camera on glasses would capture the surroundings, and software on a paired device would simplify the images into patterns of brightness, edges, and motion. Those patterns would be sent wirelessly to the implant, which would stimulate groups of neurons in the visual cortex. Each stimulated spot produces a phosphene, a point of light the person perceives, and many points together could form a rough image. The brain would learn to interpret those patterns with practice.
Musk said in 2024 that Blindsight was already working in monkeys. Neuralink has not published the details of its monkey results.
Regulatory milestones
Blindsight received FDA Breakthrough Device Designation in September 2024, as Neuralink announced. In May 2025, Neuralink received a second designation, for speech restoration. The designations speed up FDA review but do not approve a device.
In April 2025, Musk said Blindsight could work for people blind from birth. In September 2025, he said Neuralink aimed to restore limited sight in 2026. Neuralink's Telepathy device had 21 participants as of January 28, 2026, which gives the company surgical and safety experience that Blindsight will build on.
Blindsight compared with eye prosthetics
Retinal prosthetics, including Science Corporation's, stimulate surviving cells in the retina. They can help people with certain eye diseases but cannot help when the retina or optic nerve is badly damaged. Blindsight aims to avoid that limit by stimulating the visual cortex directly.
Retinal implants restored partial sight in 2025 trials, though at low resolution and for a narrow group of patients. Cortical implants like Blindsight could reach more people if they work, but they have not yet been tested by Neuralink in humans.
What comes next
Musk said human trials would begin in 2026; none had launched as of October 2026. Internal projections reported by Bloomberg in July 2025 targeted Blindsight approval by 2030 and 20,000 implants a year across Neuralink's products by 2031.
This article was first published in October 2025 and corrected in October 2026; the latest patient count is on the patient table.
